A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.
Authors | |
Keywords | |
Abstract | Many human cancers are resistant to immunotherapy, for reasons that are poorly understood. We used a genome-scale CRISPR-Cas9 screen to identify mechanisms of tumor cell resistance to killing by cytotoxic T cells, the central effectors of antitumor immunity. Inactivation of >100 genes-including , , and , which encode components of the PBAF form of the SWI/SNF chromatin remodeling complex-sensitized mouse B16F10 melanoma cells to killing by T cells. Loss of PBAF function increased tumor cell sensitivity to interferon-γ, resulting in enhanced secretion of chemokines that recruit effector T cells. Treatment-resistant tumors became responsive to immunotherapy when was inactivated. In many human cancers, expression of and inversely correlated with expression of T cell cytotoxicity genes, and -deficient murine melanomas were more strongly infiltrated by cytotoxic T cells. |
Year of Publication | 2018
|
Journal | Science
|
Volume | 359
|
Issue | 6377
|
Pages | 770-775
|
Date Published | 2018 02 16
|
ISSN | 1095-9203
|
DOI | 10.1126/science.aao1710
|
PubMed ID | 29301958
|
PubMed Central ID | PMC5953516
|
Links | |
Grant list | R01 CA173750 / CA / NCI NIH HHS / United States
U24 CA224316 / CA / NCI NIH HHS / United States
T32 GM074897 / GM / NIGMS NIH HHS / United States
R01 HG008927 / HG / NHGRI NIH HHS / United States
T32 CA207021 / CA / NCI NIH HHS / United States
|